LN Future (LNFI) H2 2024 earnings summary

Executive summary

• Revenue for 2024 was SEK 22.6 million, down 12% year-over-year, mainly due to a warehouse flood disrupting sales in all markets.

• EBIT improved by 58% to SEK -1.3 million for the year, despite lower sales, supported by insurance compensation.

• Bruttomarginal increased to 54% (from 53%), and cash flow for the year was SEK 1.3 million, up from SEK 0.3 million.

• Strong sales growth in Sweden (+11%) and Germany (+4%), which together accounted for 54% of total sales.

• Distribution expanded in Sweden (Kronans Apotek) and Denmark (Matas Group), with further growth expected in 2025.

Financial highlights

• Net sales: SEK 22.6 million (SEK 25.6 million in 2023), a decrease of 11.7%.

• EBIT: SEK -1.3 million (SEK -3.0 million in 2023), a 58% improvement.

• EBITDA: SEK -1.2 million (SEK -3.0 million in 2023).

• EPS: SEK -0.11 (SEK -0.27 in 2023).

• Cash flow: SEK 1.3 million (SEK 0.3 million in 2023).

• Bruttomarginal: 54% (53% in 2023).

• Equity: SEK 4.5 million (SEK 5.8 million in 2023).

• Soliditet: 49% (57% in 2023).

Outlook and guidance

• Inventory levels have normalized post-flood, supporting a return to previous growth trends.

• Expanded distribution in Sweden and Denmark is expected to drive growth in 2025.

• Strategic review ongoing to maximize shareholder value, led by new chairman Sven Mattsson.